The 63 linked references in paper G. NURULLINA M., G. AKHMADULLINA I., O. KRASNOPEROVA V., M. ALEKSEEVA M., O. ALEKSANDROVA V., A. CHERNOVA V., Г. НУРУЛЛИНА М., Г. АХМАДУЛЛИНА И., О. КРАСНОПЕРОВА В., М. АЛЕКСЕЕВА М., О. АЛЕКСАНДРОВА В., А. ЧЕРНОВА В. (2018) “ФАКТОРЫ РИСКА НИЗКОЭНЕРГЕТИЧЕСКИХ ПЕРЕЛОМОВ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА // RISK FACTORS OF LOW-ENERGY FRACTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS” / spz:neicon:ksma:y:2018:i:4:p:115-123

  1. 08. 2. Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop. 2016; 7: 171-181. DOI: 10.5312/wjo.v7.i3.171
  2. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. и рабочая группа авторов. Фeдeрaльныe клиничecкиe рeкoмeндaции пo диaгнocтикe, лeчeнию и прoфилaктикe ocтeoпoрoзa. Проблемы эндокринологии. 2017; 63(6): 392-426. [Melnichenko GA, Belaya Zh. E., Rozhinskaya L. Ya. and a working group of authors. I. Federal clinical recommendations on diagnostics, treatment and prevention of osteoporosis. Problems of endocrinology. 2017; 63(6): 392-426. (In Russ.)]. DOI:10.14341/probl2017636392-426
  3. Дедов И.И., Шестакова М.В., Майоров А.Ю. и рабочая группа авторов. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Москва: УП ПРИНТ, 2017. 112 с. [ Dedov II, Shestakova MV, Mayorov AYu and working group of authors. Algorithms of specialized medical care for patients with diabetes mellitus. The 8th issue. Moscow: UP Print, 2017. 112 p. (In Russ.)] DOI: 10.14341/DM20171S8
  4. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007; 18(4): 427-444. DOI: 10.1007/ s00198-006-0253-4
  5. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012; 27(11): 2231-2237. DOI: 10.1002/jbmr.1759
  6. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001; 86(1): 32-38. DOI: 10.1210/jcem.86.1.7139
  7. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005; 48: 1292-1299. DOI: 10.1007/s00125-005-1786-3
  8. Fraser LA, Pritchard J, Ioannidis G. Giangegorio LM, Adachi JD, Papaioannou A, Leslie WD. Clinical risk factors for fracture in diabetes: a matched cohort analysis. J Clin Densitom. 2011; 14(4): 416-421. DOI: 10.1016/j.jocd.2011.06.007
  9. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008; 23: 1334-1342. DOI: 10.1359/jbmr.080323
  10. Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castaño-Betancourt MC, Estrada K, Stolk L, Oei EH, van Meurs JB, Janssen JA, Hofman A, van Leeuwen JP, Witteman JC, Pols HA, Uitterlinden AG, Klaver CC, Franco OH, Rivadeneira F. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care. 2013; 36: 1619-1628. DOI: 10.2337/dc12-1188
  11. Nielson CM, Marshall LM, Adams AL, LeBlanc ES, Cawthon PM, Ensrud K, Stefanick ML, Barrett-Connor E, Orwoll ES; Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the Osteoporotic Fractures in Men Study (MrOS). J Bone Miner Res. 2011; 26(3): 496-502. DOI: 10.1002/jbmr.235
  12. Tanaka S, Kuroda T, Saito M, Shiraki M. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women. Osteoporos Int. 2013; 24(1): 69-76. DOI: 10.1007/s00198-012-2209-1
  13. Neglia C, Argentiero A, Chitano G, Agnello N, Ciccarese R, Vigilanza A, Pantile V, Argentiero D, Quarta R, Rivezzi M1, Di Tanna GL, Di Somma C, Migliore A, Iolascon G, Gimigliano F, Distante A, Piscitelli P. Diabetes and obesity as independent risk factors for osteoporosis: updated results from the ROIS/EMEROS Registry in a population of five thousand Post-Menopausal women living in a region characterized by heavy environmental pressure. Int J Environ Res Public Health. 2016; 13(11): E1067. DOI: 10.3390/ ijerph13111067
  14. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005; 165(14): 1612-1617. DOI: 10.1001/archinte.165.14.1612
  15. Roman de Mettelinge T, Cambier D, Calders P, Van Den Noortgate N, Delbaere K. Understanding the relationship between type 2 diabetes mellitus and falls in older adults: a prospective cohort study. PLoS One. 2013; 8(6): e67055. DOI: 10.1371/journal. pone.0067055
  16. Tilling LM, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications. 2006; 20(3): 158-162. DOI: 10.1016/j.jdiacomp.2005.06.004
  17. Patel S, Hyer S, Tweed K, Kerry S, Allan K, Rodin A, Barron J. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int. 2008; 82(2): 87-91. DOI: 10.1007/ s00223-007-9082-5
  18. Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005; 16: 1713-1720. DOI: 10.1007/s00198-005-1909-1
  19. Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017; 13: 455-468. DOI: 10.2147/TCRM.S131945.
  20. Ruppert K, Cauley J, Lian Y, Zgibor JC, Derby C, Solomon DH. The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study. Osteoporos Int. 2018; 29(2): 347-354. DOI: 10.1007/s00198-017-42769.
  21. Wallander M, Axelsson KF, Nilsson AG, Lundh D, Lorentzon M. Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly: A Study From the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO). J Bone Miner Res. 2017; 32(3): 449-460. DOI: 10.1002/jbmr.3002.
  22. Rajpathak SN, Fu C, Brodovicz KG, Engel SS, Lapane K. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. Drugs Aging. 2015; 32: 321-327. DOI: 10.1007/s40266-015-0254-0
  23. Vianna AGD, de Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Borba VZC, Barreto FC. Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial. Diabetol Metab Syndr. 2017; 9(1): 35. DOI:10.1186/s13098-017-0232-2.
  24. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31(5): 845-851. DOI:10.2337/dc07-2270.
  25. Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015; 36(2): 194-213. DOI:10.1210/er.2012-1042.
  26. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009; 169(15): 1395-1402. DOI:10.1001/archinternmed.2009.214.
  27. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168(8): 820. DOI:10.1001/archinte.168.8.820.
  28. Lecka-Czernik B. Safety of antidiabetic therapies on bone. Clin Rev Bone Min Metab. 2013; 11(1): 49-58. DOI:10.1007/ s12018-012-9129-7.
  29. Kasai T, Bandow K, Suzuki H, Chiba N, Kakimoto K, Ohnishi T, Kawamoto S, Nagaoka E, Matsuguchi T. Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol. 2009; 221(3): 740-749. DOI:10.1002/jcp.21917.
  30. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, Bai XC. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011; 112(10): 2902-2909. DOI:10.1002/ jcb.23206.
  31. Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J. Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE. 2015; 10(7): 1-15. DOI:10.1371/journal.pone.0132744.
  32. Bunck MC, Eliasson B, Cornér A, Heine RJ, Shaginian RM, Taskinen MR, Yki-Järvinen H, Smith U, Diamant M. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13(4): 374-377. DOI:10.1111/j.1463-1326.2010.01355.x.
  33. Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, Zhu D, Weng J. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2015; 52(6): 1083-1091. DOI:10.1007/s00592-015-0792-2.
  34. Su B, Sheng H, Zhang M, Bu L, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015; 48(1): 107-115. DOI:10.1007/s12020-014-0361-4.
  35. Driessen JH, Henry RM, van Onzenoort HA, Lalmohamed A, Burden AM, Prieto-Alhambra D, Neef C, Leufkens HG, de Vries F. Bone fracture risk is not associated with the use of glucagon- like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. 2015; 97(2): 104-112. DOI:10.1007/s00223-015-9993-5.
  36. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, Bollag WB, Bollag RJ, Hamrick M, Insogna K, Isales CM. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007; 292(2): E543-548. DOI:10.1152/ajpendo.00364.2006.
  37. Nuche-Berenguer B, Portal-Núñez S, Moreno P, González N, Acitores A, López-Herradón A, Esbrit P, Valverde I, Villanueva-Peñacarrillo ML. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMPlinked GLP-1 receptor. J Cell Physiol. 2010; 225(2): 585-92. DOI:10.1002/jcp.22243.
  38. Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res. 2005; 20(9): 1497-506. DOI:10.1359/JBMR.050524.
  39. Xie D, Zhong Q, Ding K-H, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007; 40(5): 1352-60. DOI:10.1016/j.bone.2007.01.007.
  40. Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016; 81(1): 78-88. DOI:10.1111/bcp.12777.
  41. Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000; 141(3): 1228-1235. doi:10.1210/ endo.141.3.7366.
  42. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 2006; 20(7): 1644-1651. DOI:10.1210/ me.2005-0187.
  43. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008; 149(2): 574-579. DOI:10.1210/ en.2007-1292.
  44. Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J. Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE. 2015; 10(7): 1-15. DOI:10.1371/journal.pone.0132744.
  45. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34(11): 2474-6. DOI:10.2337/dc11-1099.
  46. Driessen JHM, van Onzenoort HAW, Henry RMA, Lalmohamed A, van den Bergh JP, Neef C, Leufkens HG, de Vries F. Use of dipeptidylpeptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. 2014; 68: 124-130. DOI:10.1016/j. bone.2014.07.030.
  47. Fu J, Zhu J, Hao Y, Guo C, Zhou Z. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep. 2016; 6(1): 29104. DOI:10.1038/ srep29104.
  48. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016; 101(1): 157-166. DOI:10.1210/jc.2015-3167
  49. Vianna AGD, Sanches CP, Barreto FC. Review article: effects of type 2 diabetes therapies on bone metabolism. Diabetology & Metabolic Syndrome. 2017; 9: 75. DOI:10.1186/s13098-0170274-5.
  50. Mannucci E, Monami M. Bone fractures with sodium-glucose cotransporter-2 inhibitors: how real is the risk? Drug Saf. 2017; 40(2): 115-119. DOI:10.1007/s40264-016-0470-5.
  51. Alba M, Xie J, Fung A, Desai M. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016; 32(8): 1375-1385. DOI:10.1080/03007995.2016.1174 841.
  52. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16(2): 159-169. DOI:10.1111/dom.12189.
  53. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014; 85(4): 962971. DOI:10.1038/ki.2013.356.
  54. Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2017; 33(6). DOI:10.1002/dmrr.2903.
  55. Driessen JH, van Onzenoort HA, Starup-Linde J, Henry R, Burden AM, Neef C, van den Bergh JP, Vestergaard P, de Vries F. Use of glucagonlike-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. 2015; 97(5): 506-515. DOI:10.1007/s00223-015-0037-y.
  56. Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, Song YQ. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016; 18(12): 1199-1206. DOI:10.1111/dom.12742.
  57. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stähelin HB, Theiler R, Dawson-Hughes B. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012; 367: 40-49. DOI: 10.1056/NEJMoa1109617
  58. Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, Hanley DA, Pittas AG, Tjosvold L, Johnson JA. Clinical review: effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014; 99(10): 35513560. DOI: 10.1210/jc.2014-2136
  59. Yamauchi M, Kaji H, Nawata K, Takaoka S, Yamaguchi T, Sugimoto T. Role of parathyroid hormone in bone fragility of postmenopausal women with vitamin D insufficiency. Calcif Tissue Int. 2011; 88(5): 362-9. DOI: 10.1007/s00223-011-9464-6.
  60. Seddek M, Shawky El-sayed M, El-Badawy A, Abd Elaal El Sha3er М. Study of relationship between type 2 diabetes mellitus and functional hypoparathyroidism. Int. J. Adv. Res. 2016; 4(11): 1088-1094. DOI: 10.21474/IJAR01/2187.
  61. Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013; 56(2): 355-62. DOI: 10.1016/j.bone.2013.06.029.
  62. Schacter GI, Leslie WD. DXA-based measurements in diabetes: can they predict fracture risk? Calcif Tissue Int. 2017; 100(2): 150-164. DOI: 10.1007/s00223-016-0191-x
  63. Chung DJ, Choi HJ, Chung YS, Lim SK, Yang SO, Shin CS. The prevalence and risk factors of vertebral fractures in Korean patients with type 2 diabetes. J Bone Miner Metab. 2013; 31(2): 161-168. DOI: 10.1007/s00774-012-0398-5 Поступила / Received 16.05.2018